Arno Therapeutics, Inc. About UsPipelineInvestor RelationsContact Us
Creating the next generation of cancer treatments
Pipeline
Pipeline Chart AR-12 AR-67 AR-42

AR-67


AR-67 is a novel, third-generation camptothecin analogue that inhibits Topoisomerase I activity. In 2008, we completed a multi-centered, ascending-dose Phase I clinical trial of AR-67 in patients with advanced solid tumors. AR-67 is currently being studied in a Phase II clinical trial in patients with glioblastoma multiforme (GBM), a highly aggressive form of brain cancer.

CLINICAL PROGRAM
For information about the current clinical program, please go to [ LINK HERE ] 		Corporate Fact Sheet

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(973) 267-0101 Fax
info@arnothera.com


©2011 Arno Therapeutics, Inc. | Privacy Policy